Goldman Sachs Group Inc. Makes New Investment in Sanuwave Health Inc. $SNWV

Key Points

• Goldman Sachs Group Inc. has acquired a new position in Sanuwave Health, purchasing 9,539 shares valued at approximately $337,000, signifying a growing interest in the company among institutional investors.
• Several brokerages have raised their target prices for Sanuwave Health, with Roth Capital and Northland Securities setting a target of $55.00, while the stock currently holds a consensus rating of "Buy."
• Sanuwave Health's stock recently reported quarterly earnings higher than estimates, with a revenue of $10.16 million, showcasing its financial performance despite a market cap of around $294.81 million.

Goldman Sachs Group Inc. bought a new position in shares of Sanuwave Health Inc. (NASDAQ:SNWV - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 9,539 shares of the company's stock, valued at approximately $337,000. Goldman Sachs Group Inc. owned 0.11% of Sanuwave Health as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently added to or reduced their stakes in the company. Solas Capital Management LLC acquired a new stake in shares of Sanuwave Health in the first quarter valued at approximately $20,658,000. AWM Investment Company Inc. bought a new position in shares of Sanuwave Health in the first quarter valued at about $18,153,000. Finally, Strategic Investment Solutions Inc. IL acquired a new stake in shares of Sanuwave Health in the 1st quarter valued at approximately $47,000. 42.53% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have issued reports on SNWV. Roth Capital upped their target price on Sanuwave Health from $54.00 to $55.00 and gave the stock a "buy" rating in a research note on Friday, August 22nd. Northland Securities started coverage on Sanuwave Health in a report on Wednesday, September 3rd. They set an "outperform" rating and a $55.00 price target for the company. Northland Capmk raised Sanuwave Health to a "strong-buy" rating in a research note on Wednesday, September 3rd. Finally, Wall Street Zen cut shares of Sanuwave Health from a "buy" rating to a "hold" rating in a report on Saturday, September 20th. One analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the stock. According to data from MarketBeat.com, Sanuwave Health has a consensus rating of "Buy" and an average price target of $55.00.

Sanuwave Health Stock Down 1.2%

Sanuwave Health stock opened at $34.40 on Friday. The company's fifty day moving average is $37.77. The firm has a market cap of $294.81 million, a P/E ratio of -4.17 and a beta of 1.39. Sanuwave Health Inc. has a 12-month low of $5.63 and a 12-month high of $46.58.

Sanuwave Health (NASDAQ:SNWV - Get Free Report) last announced its earnings results on Friday, August 8th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.10. The company had revenue of $10.16 million for the quarter, compared to the consensus estimate of $10.14 million. Sanuwave Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS.

Sanuwave Health Profile

SANUWAVE Health, Inc, a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures.

Want to see what other hedge funds are holding SNWV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanuwave Health Inc. (NASDAQ:SNWV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.